Brukinsa, Calquence see growth in BTK market

While first-in-class Imbruvica ibrutinib is still the best-selling BTK inhibitor, recently launched molecules are making inroads into the BTK market.

Brukinsa zanubrutinib from BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235) has shown the strongest growth among its peers, in particular since December 2022 when the biotech reported final data from the Phase III ALPINE trial head-to-head with Imbruvica that showed superior overall response rate (ORR), progression-free survival (PFS) and discontinuation rates in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). ...